|Bid||2.3800 x 1200|
|Ask||2.4500 x 1300|
|Day's range||2.3200 - 2.4900|
|52-week range||1.7600 - 12.1700|
|Beta (5Y monthly)||-0.10|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
The big shareholder groups in Tiziana Life Sciences PLC ( LON:TILS ) have power over the company. Institutions often...
As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences (TLSA).